Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Entrada Therapeutics, Inc.TRDA · Entity 2163 | President, Research & Develop. | September 02, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Entrada Therapeutics, Inc.
Report date September 02, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 214,238 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Tax withholding · Disposed 2,079 · Balance 214,238 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2022 Filed Mar 3, 2022 21:10 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 69,525 | $0.00 Strike: $11.57 | $0.00 |
DisclosureSEC source: 0001104659-22-030008 · tm228284-4_4seq1.xml · derivative · entry 2 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,525 Underlying: Common stock · 69,525 shares Expires 2032-03-01 F3 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2023, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2026. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:10 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 11,588 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-030008 · tm228284-4_4seq1.xml · nonDerivative · entry 1 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,350 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2023; (ii) 25% on March 1, 2024; (iii) 25% on March 1, 2025 and (iv) the remaining 25% on March 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2023; (ii) 25% on March 1, 2024; (iii) 25% on March 1, 2025 and (iv) the remaining 25% on March 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F2 · balance_after: Consists of (i) 118,836 shares of common stock, (ii) 25,926 shares of restricted common stock issued upon early exercise of stock options, and (iii) 11,588 RSUs reported in this transaction. Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 23:02 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 243,639 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001104659-21-132481 · tm2131250-14_4seq1.xml · derivative · entry 1 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,639 Underlying: Common stock · 243,639 shares Expires 2031-10-28 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments commencing on October 28, 2021 (the "Vesting Start Date"), such that the option shares shall be fully vested on the four-year anniversary of the Vesting Start Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.